BridgeBio Pharma reported positive late‑stage data for encaleret in an autosomal dominant form of hypoparathyroidism and signaled plans to pursue regulatory filings, marking back‑to‑back Phase III successes for the firm. Encaleret normalized serum and urine calcium targets in a substantial fraction of treated patients versus controls, the company said. BridgeBio highlighted that 76% of treated patients reached dual calcium endpoints at 24 weeks compared with 4% on conventional therapy, and that parathyroid hormone levels improved in most recipients. The company plans to submit data to regulatory agencies and expects to file for approval next year. The results add to BridgeBio’s rare‑disease momentum after another successful Phase III readout earlier in the week; the wins could materially re‑rate the company’s pipeline value and stimulate partnership interest for commercialization. Regulators will review the full datasets and safety profile ahead of filing decisions.